Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Income from Continuing Operations over the past 9 years, most recently at 11034000.0 for Q4 2023.

  • For Q4 2023, Income from Continuing Operations fell 2.2% year-over-year to 11034000.0; the TTM value through Dec 2023 reached 47988025.0, down 20.47%, while the annual FY2024 figure was 4439000.0, 109.07% up from the prior year.
  • Income from Continuing Operations for Q4 2023 was 11034000.0 at Corbus Pharmaceuticals Holdings, down from 10468000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 2153929.0 in Q2 2019 and troughed at 38126044.0 in Q2 2020.
  • A 5-year average of 17119251.05 and a median of 14644802.0 in 2021 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: surged 117.76% in 2019 and later crashed 1870.07% in 2020.
  • Year by year, Income from Continuing Operations stood at 27038834.0 in 2019, then rose by 23.03% to 20812313.0 in 2020, then soared by 51.96% to 9998361.0 in 2021, then fell by 7.99% to 10796820.0 in 2022, then dropped by 2.2% to 11034000.0 in 2023.
  • Business Quant data shows Income from Continuing Operations for CRBP at 11034000.0 in Q4 2023, 10468000.0 in Q3 2023, and 9189000.0 in Q2 2023.